Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNR844-Cl in Presbyopia
NCT03809611Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in presbyopia comparing UNR844-Cl with Placebo (2 arms). Primary endpoint: Change in Binocular Distance-corrected Near Visual Acuity (DCNVA) From Baseline at Month 3. Started Apr 2019; status: completed.
02
Drugs
lipoic acid choline ester
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT03809611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809611.